New Diabetes Drugs May Also Improve Kidney Health
The renal protective effects seen with the SGLT2 inhibitor canogliflizin may be independent of glycemic control, suggest authors of a new post-hoc analysis.
Source: ConsultantLive - Category: Internal Medicine Authors: Scott Harris Source Type: news
More News: Diabetes | Endocrinology | Health | Internal Medicine | SGLT2 Inhibitors | Urology & Nephrology